Novel radiotracer meets gold standard for imaging prostate cancer

(Society of Nuclear Medicine and Molecular Imaging) The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting malignant prostate cancer lesions, according to research published in the April issue of The Journal of Nuclear Medicine. With this new option and 68Ga-PSMA-11, which is already widely used, nuclear medicine departments will have two effective options for staging of prostate cancer, potentially increasing availability for patients worldwide.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news